Boston Scientific Corp. will expand its portfolio of minimally invasive heart devices through the acquisition of Swiss devicemaker Symetis for $435 million.
Symetis develops minimally-invasive transcatheter aortic valve implantation devices for patients with severe heart disease.
The company's heart devices are "strongly complementary to our cornerstone Lotus valve platform, and this compelling combination of technologies will allow us to provide interventional cardiologists and cardiac surgeons with multiple TAVI offerings for varying patient pathologies and anatomy," Ian Meredith, MD, executive vice president and global CMO of Boston Scientific, said in a statement.
The deal is expected to close in the second quarter of 2017.
More articles on supply chain:
How SSM Health's pharmacy concierge program helps patients manage high drug costs
Viewpoint: US should strengthen existing laws to lower drug prices — not make new ones
Mexico border tax could lead to medical device shortages: 4 things to know